Mitochondrial Peptides PGC-1α and MOTS-c Track Heart Health After Valve Surgery
Background
Patients undergoing Aortic Valve Replacement (AVR) often experience significant surgical stress, which can impact cardiac function and recovery. Mitochondrial dysfunction is increasingly recognized as a critical factor in the progression of heart disease and post-surgical complications. While PGC-1α (a master regulator of mitochondrial biogenesis) and MOTS-c (a mitochondrial-derived peptide involved in metabolic regulation) are known to reflect metabolic health, their role as circulating biomarkers for mitochondrial status and outcomes in AVR patients has been largely unexplored.
Results
The study revealed significant and dynamic changes in both mitochondrial biomarkers following AVR. Circulating PGC-1α levels demonstrated a substantial 35% decrease (p<0.001) 24 hours post-surgery compared to baseline, indicating acute mitochondrial stress, with only partial recovery by day 7. Conversely, MOTS-c levels exhibited an initial 20% increase (p<0.01) 24 hours post-surgery, suggesting a potential compensatory metabolic response to the surgical insult. A key finding emerged regarding pre-operative levels: Patients with lower pre-operative MOTS-c levels (below 1.5 ng/mL) had a 2.8-fold higher risk (p=0.03) of developing post-operative atrial fibrillation. Furthermore, a strong inverse correlation was observed between the magnitude of post-operative PGC-1α decline and the duration of mechanical ventilation (r=-0.45, p<0.001), highlighting its potential as a prognostic indicator.
Why It Matters
Circulating PGC-1α and MOTS-c could serve as novel, non-invasive biomarkers for assessing mitochondrial health, predicting post-operative complications, and stratifying risk in AVR patients. This could enable earlier identification of high-risk individuals, allowing for more personalized perioperative management strategies and potentially guiding targeted interventions to improve recovery. Ultimately, these findings pave the way for future clinical trials investigating mitochondrial-targeted therapies to enhance patient outcomes in cardiac surgery. Further research is essential to validate these findings in larger, multi-center cohorts and explore their utility in other cardiac surgical settings.